Market Overview

Roth Capital Defends Questcor, Says Buy the Dip

Related QCOR
Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest PEG Ratio
Why A 5% To 10% Market Correction May Be In The Cards

Shares of Questcor Pharma (NASDAQ: QCOR) are down 6.5 percent Friday afternoon following reports on Thursday of an Aetna (NYSE: AET) review which showed H.P. Acthar was "medically necessary" only for infants with seizures.

Roth Capital analyst Yale Jen called the sell off a chance to buy some stock. Jen noted the bulletin on Thursday was nearly "identical" to the prior policy update from September. The analyst believes the bulletin does not add "negativity" to Questcor fundamentals.

Roth Capital maintains a Buy rating and $47 price target on shares of Questcor.

Posted-In: Analyst Color Analyst Ratings Movers

 

Most Popular

Related Articles (QCOR + AET)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters